Semnur stockholders elect director, ratify auditor, approve 2025 equity plans at annual meeting

Semnur Pharmaceuticals, Inc.

Jay Chun, M.D., Ph.D. elected Class I director with 200,166,258 for, 3,804 withheld, 137,409 broker non-votes.
Ratification of Pipara & Co LLP as auditor for FY 2026: 200,307,425 for, 46 against, 0 abstentions.
2025 Equity Incentive Plan approved: 200,166,256 for, 269 against, 3,537 abstentions, 137,409 broker non-votes.
2025 Employee Stock Purchase Plan approved: 200,166,255 for, 270 against, 3,537 abstentions, 137,409 broker non-votes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.